Guinea vs Mauritania: Share of the population living with HIV receiving antiretroviral therapy
Guinea
74.5%
in 2024
Mauritania
75.8%
in 2024
Guinea rank
66th
Mauritania rank
64th
Share of the population living with HIV receiving antiretroviral therapy over time
- Guinea
- Mauritania
How they compare
Mauritania currently reports 75.8% against 74.5% in Guinea, a difference of 1.3%.
The two have swapped places 6 times across 35 shared years of data; in 1990 it was Mauritania ahead.
Guinea ranks 66th and Mauritania ranks 64th of 149 countries.
Mauritania has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Guinea | Mauritania | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 3.9% | 4.1% | 0.2% | Mauritania |
| 2010s | 28.3% | 31.9% | 3.6% | Mauritania |
| 2020s | 60.8% | 64.3% | 3.4% | Mauritania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Guinea or Mauritania?
- Mauritania, at 75.8% against 74.5% in Guinea as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Guinea and Mauritania?
- 1.3%, with Mauritania ahead.
- How many years of comparable data are there for Guinea and Mauritania?
- 35 years are reported by both, from 1990 to 2024.
- How do Guinea and Mauritania rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Guinea ranks 66th and Mauritania ranks 64th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.